Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays
University and Regional Laboratories Region Skåne, Malmö, Sweden.
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center for Diagnostics, Department of Clinical Chemistry.
University and Regional Laboratories Region Skåne, Malmö, Sweden.
Show others and affiliations
2014 (English)In: Journal of Thrombosis and Haemostasis, ISSN 1538-7933, E-ISSN 1538-7836, Vol. 12, no 9, 1545-1553 p.Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION:

Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays constitute clinically valuable information.

OBJECTIVES:

To investigate the effects of apixaban on commonly used coagulation methods, and to evaluate anti-FXa assays for specific determination of the drug concentration.

MATERIALS AND METHODS:

Apixaban was added to plasma from healthy subjects in the concentration range 0-1000 μg L(-1) , and analyses were performed with different reagents for activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin, protein C, and protein S. A lupus anticoagulant assay and an APTT assay with varying phospholipid concentrations were used to study the phospholipid dependence.

RESULTS:

In general, apixaban showed fewer effects in vitro than have been shown for rivaroxaban, another direct FXa inhibitor. The concentration needed to double the APTT varied between 2200 and 4700 μg L(-1) , and the concentration needed to double the PT varied between 700 and 3900 μg L(-1) . The effects on antithrombin, protein C and protein S assays were dependent on the type of reagent. Apixaban did not cause false-positive lupus anticoagulant results. Chromogenic anti-FXa assays showed linear dose-response curves with apixaban.

CONCLUSIONS:

Therapeutic concentrations of apixaban variably affect different assay groups, and even different reagents within an assay group. The effects were much smaller than with rivaroxaban. The use of APTT and/or PT assays to screen the anticoagulant activity of apixaban cannot be recommended. A chromogenic anti-FXa assay can be used for reliable measurements of apixaban concentration.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2014. Vol. 12, no 9, 1545-1553 p.
Keyword [en]
analysis; anticogaulants; apixaban; blood coagulation tests; factorXa
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-111458DOI: 10.1111/jth.12649ISI: 000342143900023PubMedID: 24965851OAI: oai:DiVA.org:liu-111458DiVA: diva2:757216
Note

Funding Agencies|Bristol Meyers Squibb

Available from: 2014-10-21 Created: 2014-10-17 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

fulltext(960 kB)265 downloads
File information
File name FULLTEXT01.pdfFile size 960 kBChecksum SHA-512
be45c76e730e357759161d4c4e96c9c88f6d164e5b6063cedc4e4837e76613c1973794fd988dd249e03b4bcdf28789853ae8a2a70d2feea85771f23f16d5f3e3
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Gustafsson, KerstinFaxälv, LarsLindahl, Tomas
By organisation
Department of Clinical and Experimental MedicineFaculty of Health SciencesDivision of Microbiology and Molecular MedicineDepartment of Clinical Chemistry
In the same journal
Journal of Thrombosis and Haemostasis
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 265 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 155 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf